MX2020007531A - Aminopirrolotriazinas como inhibidores de cinasa. - Google Patents

Aminopirrolotriazinas como inhibidores de cinasa.

Info

Publication number
MX2020007531A
MX2020007531A MX2020007531A MX2020007531A MX2020007531A MX 2020007531 A MX2020007531 A MX 2020007531A MX 2020007531 A MX2020007531 A MX 2020007531A MX 2020007531 A MX2020007531 A MX 2020007531A MX 2020007531 A MX2020007531 A MX 2020007531A
Authority
MX
Mexico
Prior art keywords
aminopyrrolotriazines
kinase inhibitors
compounds
formula
ripk1
Prior art date
Application number
MX2020007531A
Other languages
English (en)
Spanish (es)
Inventor
Scott Hunter Watterson
Carolyn Diane Dzierba
Amy C Hart
Zhizhen Barbara Zheng
William J Pitts
Brian Lee Venables
Guanglin Luo
Jianliang Shi
Jie Chen
Hua Gong
Carolyn A Weigelt
John E Macor
Junqing Guo
Murugaiah Subbaiah Murugaiah Andappan
Jason M Guernon
Yong-Jin Wu
Sing-Yuen Sit
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020007531A publication Critical patent/MX2020007531A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2020007531A 2018-01-26 2019-01-24 Aminopirrolotriazinas como inhibidores de cinasa. MX2020007531A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622415P 2018-01-26 2018-01-26
PCT/US2019/014918 WO2019147782A1 (en) 2018-01-26 2019-01-24 Aminopyrrolotriazines as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2020007531A true MX2020007531A (es) 2020-09-09

Family

ID=65363405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007531A MX2020007531A (es) 2018-01-26 2019-01-24 Aminopirrolotriazinas como inhibidores de cinasa.

Country Status (16)

Country Link
US (1) US11618753B2 (https=)
EP (1) EP3743430B1 (https=)
JP (1) JP7307734B2 (https=)
KR (1) KR102759231B1 (https=)
CN (1) CN112262139B (https=)
AR (1) AR114186A1 (https=)
AU (1) AU2019211382B2 (https=)
BR (1) BR112020014516A2 (https=)
CA (1) CA3088548A1 (https=)
EA (1) EA202091777A1 (https=)
ES (1) ES2959399T3 (https=)
IL (1) IL276269A (https=)
MX (1) MX2020007531A (https=)
SG (1) SG11202007035YA (https=)
TW (1) TW201940485A (https=)
WO (1) WO2019147782A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47460A (fr) 2017-02-13 2019-12-18 Bristol Myers Squibb Co Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
HUE058292T2 (hu) 2017-10-30 2022-07-28 Bristol Myers Squibb Co Aminoimidazopiridazinok mint kináz inhibitorok
AU2019339355A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
ES2969756T3 (es) 2019-10-03 2024-05-22 Bristol Myers Squibb Co Indazol carboxamidas como inhibidores de cinasas
JPWO2021157596A1 (https=) * 2020-02-07 2021-08-12
WO2022007921A1 (zh) * 2020-07-10 2022-01-13 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
CN111925345B (zh) * 2020-08-21 2023-09-29 上海科利生物医药有限公司 一种手性2-氨甲基四氢呋喃的制备方法
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
JPWO2022172889A1 (https=) * 2021-02-10 2022-08-18
CN113563214B (zh) * 2021-07-06 2024-02-02 山东鲁泰控股集团有限公司石墨烯高分子复合材料研发中心 一种氨基乙酸的合成方法
CN113527220A (zh) * 2021-07-26 2021-10-22 京博农化科技有限公司 一种脱硫丙硫菌唑异构体的合成方法
CN116574053B (zh) * 2022-06-21 2026-04-14 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2627839C (en) 2005-11-02 2014-08-19 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
EP2385053B1 (en) * 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
HRP20160967T1 (hr) 2009-10-06 2016-10-07 Millennium Pharmaceuticals, Inc. Heterociklički spojevi korisni kao pdk1 inhibitori
CN102918045A (zh) 2010-03-31 2013-02-06 百时美施贵宝公司 作为蛋白激酶抑制剂的取代的吡咯并三嗪
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US10023576B2 (en) * 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
US10214537B2 (en) * 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
MD3436461T2 (ro) 2016-03-28 2024-05-31 Incyte Corp Compuși pirolotriazină ca inhibitori TAM
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
MA47460A (fr) 2017-02-13 2019-12-18 Bristol Myers Squibb Co Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
HUE058292T2 (hu) 2017-10-30 2022-07-28 Bristol Myers Squibb Co Aminoimidazopiridazinok mint kináz inhibitorok
AU2019339355A1 (en) 2018-09-13 2021-05-13 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드

Also Published As

Publication number Publication date
IL276269A (en) 2020-09-30
CN112262139A (zh) 2021-01-22
EA202091777A1 (ru) 2020-10-14
BR112020014516A2 (pt) 2020-12-08
AU2019211382B2 (en) 2022-06-16
KR20200115550A (ko) 2020-10-07
EP3743430A1 (en) 2020-12-02
AR114186A1 (es) 2020-07-29
CA3088548A1 (en) 2019-08-01
CN112262139B (zh) 2023-07-25
EP3743430B1 (en) 2023-08-02
TW201940485A (zh) 2019-10-16
WO2019147782A1 (en) 2019-08-01
SG11202007035YA (en) 2020-08-28
JP7307734B2 (ja) 2023-07-12
JP2021511363A (ja) 2021-05-06
US20200347071A1 (en) 2020-11-05
KR102759231B1 (ko) 2025-01-22
AU2019211382A1 (en) 2020-09-17
US11618753B2 (en) 2023-04-04
ES2959399T3 (es) 2024-02-26

Similar Documents

Publication Publication Date Title
MX2020007531A (es) Aminopirrolotriazinas como inhibidores de cinasa.
CL2021003373A1 (es) Nuevos inhibidores de egfr
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
CO2017010583A2 (es) Compuestos de pirazol y método para elaborar y usar los compuestos
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
MX2019007540A (es) Derivados de pirazol como inhibidores de malt1.
CO7160047A2 (es) Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidérmico (egfr)
ECSP19055169A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
UY37610A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
NI201900075A (es) Compuesto moduladores del receptor de hidrocarburos de arilo (ahr)
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CL2021001461A1 (es) Moduladores de trex1
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
MX2021002215A (es) Derivados de tetrahidropiridopirimidina como moduladores de ahr.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
CO2021007006A2 (es) Moduladores de la expresión de irf5
MX2016007719A (es) Derivados de nicotinamida dialquil(oxido)-?4-sulfanilideno como inhibidores de cinasa.
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
CO2020003134A2 (es) Moduladores de la expresión de enac
UY38472A (es) Moduladores de la expresión de foxp3
MX2018004164A (es) Inhibidores de sumoilacion de crmp2 y usos de los mismos.